Johnson & Johnson to Acquire Austin's Ollin Biosciences in Up to $3.3B Biotech Deal
$3.3 Billion Ollin Biosciences Deal Highlights Busy Week for Austin Biotech and Tech
AUSTIN, Texas — Johnson & Johnson announced a definitive agreement to acquire Austin-based clinical-stage biotechnology company Ollin Biosciences in a transaction valued at up to $3.3 billion, targeting investigational bispecific antibodies for retinal conditions such as wAMD and DME. Elsewhere in Austin corporate news on Tuesday, November 17, 2026, research platform QuestionPro unveiled a strategic alliance with NielsenIQ, while Vivo Care and Onpoint Healthcare Partners combined operations to expand remote care.
UT Austin Study Reveals How Brain Amplifies Familiar Voices in Noise
In academic research, University of Texas at Austin scientists published findings showing how the human brain relies on prior experience to automatically amplify important sounds—such as speech—inside noisy rooms without conscious effort.
City Announces December 2 Open House for South Lamar Boulevard Mobility Project
On the municipal front, Austin officials scheduled a December 2 community open house to share engineering updates and gather public feedback on the South Lamar Boulevard corridor mobility improvements.
📰 Related Stories
- UT Austin's 4,000-GPU Horizon Supercomputer Opens as APD Seeks Park Burglary Suspects and TSAHC Names Next Leader Austin • Nov 17, 2026
- 14-Story Hotel Trinity Opens in Downtown Austin as Council Reviews Muny Land Pact and Cookwell Changes Hands Austin • Nov 17, 2026
- Johnson & Johnson to Acquire Austin Biotech Ollin Biosciences in Deal Worth Up to $3.3 Billion Austin • Nov 17, 2026
- San Francisco Deploys AI Cameras for Muni Lanes as Activists Protest Chase Center and Surf Hits 35 Feet San Francisco • Nov 17, 2026